Table of Contents
ISRN Microbiology
Volume 2011 (2011), Article ID 787290, 5 pages
http://dx.doi.org/10.5402/2011/787290
Research Article

Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability

1R.M. Alden Research Laboratory, Culver City, CA 90230, USA
2Department of Medicine, David Geffen School of Medicine, Los Angeles, CA 90095, USA

Received 23 August 2011; Accepted 28 September 2011

Academic Editor: P. D. Ghiringhelli

Copyright © 2011 Diane M. Citron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Jacqueline, J. Caillon, V. Le Mabecque et al., “In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 9, pp. 3397–3400, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. Mushtaq, M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore, “In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 2, pp. 300–311, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. D. Parish and N. Scheinfeld, “Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection,” Current Opinion in Investigational Drugs, vol. 9, no. 2, pp. 201–209, 2008. View at Google Scholar · View at Scopus
  4. H. S. Sader, T. R. Fritsche, K. Kaniga, Y. Ge, and R. N. Jones, “Antimicrobial activity and spectrum of PPI-0903m (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3501–3512, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. S. Sader, T. R. Fritsche, and R. N. Jones, “Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1153–1155, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. H. Talbot, D. Thye, A. Das, and Y. Ge, “Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 10, pp. 3612–3616, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Clinical and Laboratory Standards Institute, “Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition,” Clinical and Laboratory Standards Institute Document M7-A6, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2006. View at Google Scholar
  8. Clinical and Laboratory Standards Institute, “Performance standards for antimicrobial susceptibility testing; 19th informational supplement,” document M100-S19, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2009. View at Google Scholar
  9. R. N. Jones, T. R. Fritsche, Y. Ge, K. Kaniga, and H. S. Sader, “Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 6, pp. 1047–1052, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus